UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Title of each class Trading Symbol Name of each exchange on which registered Common Stock, $0.001 par value per share ALRN The Nasdaq Capital Market Emerging growth company ☐ FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transiti ...

AUSTIN, Texas, May 03, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ:ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced the closing of its previously announced underwritten registered direct offering priced at-the-market under Nasdaq rules of 4,273,505 shares of its common stock and accompanying warrants to purchase an aggregate of 4,273,50 ...

AUSTIN, Texas, May 01, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ:ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced the pricing of an underwritten registered direct offering priced at-the-market under Nasdaq rules of 4,273,505 shares of its common stock and accompanying warrants to purchase an aggregate of 4,273,505 shares of common sto ...

Low-dose LTI-03 (2.5 mg BID), a Caveolin-1 related peptide, reduced expression of multiple profibrotic proteins in both pathological basal-like cells and fibroblasts and increased the expression of a biomarker indicative of epithelial health, suggesting potential therapeutic effect Positive trend was observed in seven of eight IPF biomarkers evaluated Low-dose LTI-03 was well-tolerated, with no safety signal observed Data from Cohort 2 evaluating high-dose LTI-03 (5 mg BID) is expected in the third quarter ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38130 | --- | --- | |---------------------------------------------------------------------------------------------------------------- ...

Core Insights - Aileron Therapeutics is advancing a novel pipeline of first-in-class medicines targeting significant unmet medical needs in orphan pulmonary and fibrosis indications, with a focus on LTI-03 for idiopathic pulmonary fibrosis (IPF) and LTI-01 for loculated pleural effusion (LPE) [1][3][7] Financial Performance - As of December 31, 2023, the company reported cash, cash equivalents, and investments of $17.3 million, down from $21.2 million in 2022, with expectations to fund operations into the fourth quarter of 2024 [6][10] - Research and Development (R&D) expenses for Q4 2023 were $2.0 million, a decrease from $2.4 million in Q4 2022, primarily due to the termination of R&D activities related to ALRN-6924 [6][11] - General and Administrative (G&A) expenses for Q4 2023 were $5.3 million, up from $2.3 million in Q4 2022, attributed to the integration and operating activities of Lung [6][11] - The net loss for Q4 2023 was $7.3 million, compared to $4.5 million in Q4 2022, with a basic and diluted net loss per share of $1.54 [6][11] Business Developments - The successful merger with Lung Therapeutics in October 2023 has provided a focused pipeline and strengthened the balance sheet with $18.4 million in financing [2][3] - The company anticipates 2024 to be a pivotal year, expecting to report topline results from the Phase 1b study of LTI-03 in Q3 2024 [2][4] - LTI-03 is currently in a randomized, double-blind, placebo-controlled Phase 1b clinical trial for IPF patients, with a dual mechanism targeting both epithelial cells and fibroblasts [4][7] Pipeline Overview - LTI-01 has received Orphan Drug Designation in the US and EU and Fast Track Designation in the US, and is ready for Phase 2b trials after evaluations in Phase 1b and Phase 2a [5][7] - Aileron hosted a pulmonary care expert panel in February 2024 to discuss LTI-03's implications for IPF, featuring notable pulmonary care experts [4]

WALTHAM, Mass., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ:ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, will host a virtual key opinion leader event today from 4:30 to 5:30 p.m. ET titled "Clinical Perspectives on Treating Idiopathic Pulmonary Fibrosis" featuring pulmonary care experts Fernando J. Martinez, M.D., M.S. from Weill Cornell M ...

WALTHAM, Mass., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Aileron Therapeutics, Inc. ("Aileron") (NASDAQ:ALRN), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today announced that it will host a virtual key opinion leader event titled, "Clinical Perspectives on Treating Idiopathic Pulmonary Fibrosis" on Thursday, February 15, 2024, from 4:30 to 5:30 p.m. ET. Aileron management will be joined ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Title of each class Trading Symbol Name of each exchange on which registered Common Stock, $0.001 par value per share ALRN The Nasdaq Capital Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Comm ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Title of each class Trading Symbol Name of each exchange on which registered Common Stock, $0.001 par value per share ALRN The Nasdaq Capital Market FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commissio ...